3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Thoracic
2
Head & Neck
2
Genitourinary
2
Sarcoma
1
Other solid neoplasm
1
NET
1
Gynecologic
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Breast Neoplasms
2
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thrombocytosis
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
pembrolizumab
28
Trastuzumab
16
Paclitaxel
14
Docetaxel
12
Cyclophosphamide
11
Capecitabine
11
Nivolumab
9
fludarabine
7
Carboplatin
7
Oxaliplatin
6
Magnetic Resonance Spectroscopy
6
Cisplatin
6
Specimen Handling
5
Leucovorin
5
Irinotecan
5
Injections
5
Gemcitabine
5
Fluorouracil
5
Bevacizumab
5
atezolizumab
4
aldesleukin
4
Taxes
4
Ipilimumab
4
Fluorodeoxyglucose F18
4
Drug Therapy
4
Cetuximab
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
zanidatamab
3
veliparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
regorafenib
×
Breast
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled